Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414
Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
0
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
0
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2222190/gilead-gild-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2222190
Feb 06, 2024 - The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
https://www.zacks.com/stock/news/2222125/late-session-earnings-bonanza-ford-chipotle-snap-more?cid=CS-ZC-FT-ahead_of_wall_street-2222125
Feb 06, 2024 - Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.
0
Earnings Data Deluge
https://www.zacks.com/stock/news/2221920/earnings-data-deluge?cid=CS-ZC-FT-economic_highlights-2221920
Feb 06, 2024 - Earnings Data Deluge.
0
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More
https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221113
Feb 05, 2024 - Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
0
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2215085
Jan 24, 2024 - Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
0
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367
Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
0
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2211770/gilead-sciences-gild-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2211770
Jan 17, 2024 - In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.
0
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
https://www.zacks.com/stock/news/2206596/gilead-sciences-gild-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2206596
Jan 05, 2024 - In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.
0